FDA should have acted sooner on tests

Share this article:
FDA should have acted sooner to ban unapproved DTC genetic tests, the agency's medical devices director, Jeffrey Shuren told a House hearing after listening to disturbing results from a recent Government Accountability Office investigation. It found misleading information and deceptive marketing practices at several companies marketing the laboratory-developed tests, which have not been tightly regulated by FDA.

In an undercover operation, GAO fictitious consumers received test results that were misleading and of little or no practical use, the investigation concluded. “For example, GAO's donors often received disease risk predictions that varied across the four companies, indicating that identical DNA samples yield contradictory results,” said GAO special investigations director Gregory Kutz.

One DNA donor was told that he was simultaneously at below-average, average, and above-average risk for prostate cancer and hypertension, he said. “GAO also found 10 egregious examples of deceptive marketing, including claims made by four companies that a consumer's DNA could be used to create personalized supplements to cure diseases,” Kutz said.

Two days before the hearing, FDA told a public meeting it convened to discuss the reliability of the tests that it is moving forward with a risk-based approach for providing regulatory oversight.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?